ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Radio Host, Physician Elmer Huerta Becomes American Cancer Society President.

November 9, 2007

Panel To Take Up Issues In Grant/Peer Review System, Consider NCAB Membership Requirements

December 11, 1981

NCAB Plans Study Of Its Authorities. FDA, NIH To Provide $6.75 Million For Grants In Regulatory Science

February 26, 2010

Prostatectomy Improves Outcome In Some Men

August 29, 2008

In Congress: Senate Committee Approves 15% Increase For NCI In FY 1999; Report Urges NCI To Increase Research In Several Cancers

September 11, 1998

Studies Started On Use Of Heroin, THC for Pain, Discomfort Therapy

October 13, 1978